Mencevax ACWY™ (meningococcal vaccine): New antibody persistence data

User Rating: 1 / 5

Star ActiveStar InactiveStar InactiveStar InactiveStar Inactive

Date: 07 July 2014

Description: A Direct Healthcare Professional Communication (DHPC) has been approved by NPCB to inform healthcare professionals of the new antibody persistence data for Mencevax ACWY™. The immunity to serogroups W-135 and Y in individuals 11-55 years of age who were vaccinated two years earlier with Mencevax ACWY™ is 24.0% and 44.0%, respectively. Limited data showed a waning of serum bactericidal antibody titres against serogroup A one year post-vaccination when using human complement in the assay (hSBA). Individuals remaining at high risk of exposure to serogroups A, W-135 and Y should be considered for earlier revaccination according to local recommendations. The package insert for Mencevax ACWY™ will be updated by GlaxoSmithKline Pharmaceuticals (Malaysia) Sdn. Bhd. to reflect this new persistence data. Please refer to the DHPC for further information.


National Pharmaceutical Regulatory Agency (NPRA)

Lot 36, Jalan Universiti (Jalan Prof Diraja Ungku Aziz), 46200 Petaling Jaya, Selangor, Malaysia.

  • Phone: +603-7883 5400




The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Mobile Web :

Site Last Modified

  • Last Modified: Saturday 20 July 2024, 01:25:04.
© Copyright 2023 . All Rights Reserved National Pharmaceutical Regulatory Agency NPRA


Main Menu English